‘Ophthalmic Drugs Market Will Reach $18.7 Billion in 2012′ Visiongain Report Predicts
LONDON, March 21, 2012 /PRNewswire/ –
A new report by visiongain [http://www.visiongain.com/Content/3/About-Us ] predicts
that the world market for ophthalmic
drugs will reach $18.7 billion for 2012. That
revenue forecast appears in Ophthalmic Drugs: World Market Prospects 2012-2022
published in March 2012. Visiongain is a business information provider based in London,
From 2012 to 2022, the pharmaceutical [http://www.visiongain.com/Sector/8/Pharma ]
industry will improve treatment of ocular disorders and increase revenues from those
products. The R&D pipeline for treating eye diseases is strong. Visiongain’s study
predicts that the world market for eye drugs will grow strongly from 2012 to 2022. It will
be stimulated by increasing prevalence of eye disorders among aging populations worldwide.
Sustained-release ocular implants, gene therapy and RNA interference technology will
influence R&D in ophthalmology, as will neuroprotective agents for glaucoma. Many
commercial opportunities for ophthalmic drugs exist, with high revenues possible this
Dr Syed Ahmed, a senior pharmaceutical industry analyst at visiongain, said, “The
world market for ophthalmic drugs is an important segment of the pharma industry. The main
causes of visual impairment and sight loss in developed countries are retinal diseases.
These include age-related macular degeneration (AMD), diabetic macular oedema and macular
oedema caused by retinal vein occlusion. Glaucoma is the leading cause of irreversible
blindness. It remains a large segment of the ophthalmic prescription drug market.
Worldwide, there are many under-met treatment needs for eye disorders.
“Over coming years, there will be much research in ophthalmics, especially for
sustained release implants and injection technologies for retinal diseases. Improved drug
delivery and new formulations will be important. Sustained release formulations will offer
marked potential for revenue growth. Diabetic macular oedema (DME) will also be important
to the future of the ophthalmic drug market. The number of people developing Type II
diabetes is rising, with many diabetics developing DME. In particular, anti-VEGF therapy
will play an increasing role in the treatment of DME.”
Visiongain’s report provides revenue forecasts to 2022 at world market, therapeutic
submarket, product and national level. It forecasts world sales for the following
– Glaucoma treatments
– Anti-allergy, anti-inflammatory and anti-infective agents
– Retinal disorder treatments
– Dry eye treatments
– Other medicines.
That investigation forecasts sales of 20 leading drugs, including Lucentis, Visudyne,
Xalatan/Xalacom and Restasis. Research, data and analyses cover activities of Allergan,
Novartis, Pfizer, Roche and other pharmaceutical companies.
The analysis includes researching the R&D pipeline, interviewing authorities on the
industry and forecasting revenues in leading national markets. Countries analysed are the
US, Japan, the EU5, Brazil, China and India. Ophthalmic Drugs: World Market Prospects
2012-2022 adds to visiongain’s range of analytical reports on industries and markets in
For sample pages and further information concerning the Visiongain report Ophthalmic
Drugs: World Market Prospects 2012-2022 please visit:
For an executive summary and to order this report please contact:
Email: Sara Peerun on firstname.lastname@example.org
Acucela Alcon (Novartis) Alimera Sciences Allergan American Academy of Ophthalmology (AAO) [US] American Society of Retina Specialists (ASRS) [US] Apotex Asahi Glass Association for Research in Vision and Ophthalmology AstraZeneca Bausch & Lomb Bayer Biovitrum Bristol-Myers Squibb Can-Fite BioPharma Cerimon Pharmaceuticals Chugai Pharmaceutical Corp. CombinatoRx CoMentis Daiichi Sankyo Danube Pharmaceuticals Eli Lilly Esteve European Medicines Agency (EMEA/EMA) EyeGate Pharmaceuticals Eyetech Pharmaceuticals Food and Drug Administration (FDA) [US] Fovea Pharmaceuticals Galderma International SA (Nestle and L'Oreal) Genentech GlaxoSmithKline Gruenenthal InSite Vision Inspire Pharmaceuticals ISTA Pharmaceuticals Johnson & Johnson Kowa Company Kyorin Pharmaceutical Co. Kyowa Hakko Kirin Corp. Laboratorios Sophia LEO Pharma Lux Biosciences Meda Pharmaceuticals Merck & Co. Ministry of Health, Labour and Welfare [Japan] Moorfields Eye Hospital [UK] Mylan National Eye Institute (NEI) [US] National Health Service (NHS) [UK] National Institute for Health and Clinical Excellence (NICE) [UK] National Institutes of Health (NIH) [US] Neurotech NicOx NovaBay Pharmaceuticals Novartis Novex Ophthotech OPKO Health OSI Pharmaceuticals Othera Pharmaceuticals Otsuka Pharmaceutical Corp. Oxford Eye Hospital [UK] OXiGENE Paladin Labs Pfizer pSivida QLT Quark Pharmaceuticals Ranbaxy Laboratories Regeneron Pharmaceuticals ReVision Therapeutics Roche Rutgers University, Springfield, New Jersey [US] Santen Pharmaceutical Corp. Sanwa Kagaku Kenkyusho Corp. SARcode Corporation Senju Pharmaceuticals Shire Pharmaceuticals Sirion Therapeutics Sirna Therapeutics SKS Ocular Sunesis Pharmaceuticals Symphony ViDA Takeda Pharmaceuticals Targeted Genetics Teva Pharmaceutical Industries ThromboGenics University College of London (UCL), Institute of Ophthalmology [UK] University of Aston, Birmingham [UK] University of Oxford [UK] Watson Pharmaceuticals
Visiongain is one of the fastest growing and most innovative independent media
companies in Europe. Based in London, UK, visiongain produces a host of
business-2-business conferences, newsletters, management reports and e-zines focusing on
the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified
experts in their field. Visiongain has firmly established itself as the first port-of-call
for the business professional, who needs independent, high quality, original material to
rely and depend on.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an
e-mail to email@example.com or call her on +44(0)207-336-6100